申请人:Cassella Aktiengesellschaft
公开号:US04532239A1
公开(公告)日:1985-07-30
Basically-substituted pyridazines of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3, independently of one another, denote hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, alkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, alkoxy, hydroxyalkoxy, alkoxy-alkoxy, alkenyloxy, alkynyloxy, cycloalkoxy, phenalkoxy, alkanoyl, alkanoylamino and --NH--CO--R.sup.9, R.sup.9 representing morpholino, piperidino or 1-pyrrolididinyl, or an optionally substituted ureido radical, R.sup.4 denotes hydrogen or lower alkyl and W denotes hydrogen, chlorine or bromine; and the acid-addition salts thereof are useful alone or in pharmaceutical preparations for treating cardiac complaints, circulatory complaints and high blood pressure. Several methods for preparing the basically-substituted pyridazines are also provided.
基本上,公式为##STR1##的取代吡啶嗪化合物,其中R.sup.1、R.sup.2和R.sup.3独立地表示氢、卤素、羟基、硝基、三氟甲基、烷基、烷氧基烷基、烯基、炔基、环烷基、环烯基、苯基、烷氧基、羟基烷氧基、烷氧基-烷氧基、烯氧基、炔氧基、环烷氧基、苯基氧基、醇酰基、醇酰氨基和--NH--CO--R.sup.9,其中R.sup.9代表吗啉基、哌啶基或1-吡咯啉基,或者是一个可选择取代的脲基团,R.sup.4代表氢或低碳烷基,W代表氢、氯或溴;以及它们的酸盐,单独使用或在药物配方中用于治疗心脏疾病、循环疾病和高血压。还提供了几种制备基本取代吡啶嗪的方法。